Our Team of Dermatologists, Makeup Artists, Aestheticians, and Editors Picked The Best Skincare Products of The Year - Women's Health
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Women's Health may earn commission from the links on this page, but we only feature products we believe in. Why Trust Us? Kolby KnightThere’s a difference between having options and having so many that you’re almost paralyzed by the thought of choosing. Throw in the possibility of spending hard-earned money on lackluster stuff and it’s no wonder that shopping for skin care products in 2026 feels so...hard. No longer. The 2026 Women’s Health Skincare Awards features 88 products vetted by an esteemed panel of experts, including dermatologists, aestheticians, and our own editors. The face wash that cleans without stripping your skin, the serum that plumps instantly and over time, the scalp sunscreen that won’t weigh down hair—great skin starts (and continues) here. How We ChoseFor this year's annual skincare awards package—our biggest ever—the Women's Health beauty team consulted with an esteemed panel of 14 leading experts to select the best-of-the-best products across face, body, eyes & lips, hands & feet, and scalp (a new category).
This article is an excerpt. To read the full content, visit the original source. Women's Health
Related articles
Cetaphil Maker Galderma to Buy ZO Skin Health for $1.5 Billion in Medical Skincare Push - Law Commentary
Galderma, the Swiss dermatology company behind Cetaphil and Alastin, has agreed to buy ZO Skin Health for $1.5 billion in cash, giving the company a much larger position in physician-dispensed skincare sold through dermatologists, plastic surgeons and medical spas. The acquisition, announced October 14, 2026, would give Galderma 100% ownership of the California-based skincare company from shareholders including Blackstone and the Obagi family. Galderma expects the transaction to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other closing conditions.
Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group
Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.
0 comments
No comments yet. Be the first to share your thoughts!